With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...
Massive cuts at the FDA have hit staff tied to drug reviews and user fees, putting future approvals in jeopardy, according to multiple reports.
As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...
Funnyman Kenan Thompson is opening up about the not-so-funny experience of living with gastroesophageal reflux disease (GERD) ...
Several pharma CEOs met with Chinese President Xi Jinping in Beijing. President Donald Trump's reciprocal tariffs have mostly ...
Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...
Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...
In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...
Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors
When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...
In a statement, Nxera CEO Chris Cargill said Kaneko’s appointment will help the company “maximize our commercial activities ...
Havas Lynx New York also hired Megan Skelly as chief creative officer. Skelly’s 30-year career has included spells at agencies including Edelman, R/GA, 360i and Dentsu.
With concerns mounting and speculation swirling, the particulars of President Donald Trump’s much-touted “Liberation Day” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback